IS2848B - Súksínat- og malónatsalt af trans-4-(1R,3S)-6-klór-3-fenýlindan-1-ýl)-1,2,2-trímetýlpíperasíni og notkun sem lyf - Google Patents
Súksínat- og malónatsalt af trans-4-(1R,3S)-6-klór-3-fenýlindan-1-ýl)-1,2,2-trímetýlpíperasíni og notkun sem lyfInfo
- Publication number
- IS2848B IS2848B IS8265A IS8265A IS2848B IS 2848 B IS2848 B IS 2848B IS 8265 A IS8265 A IS 8265A IS 8265 A IS8265 A IS 8265A IS 2848 B IS2848 B IS 2848B
- Authority
- IS
- Iceland
- Prior art keywords
- phenylindan
- trimethylpiperazine
- succinate
- trans
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
- C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49605803P | 2003-08-18 | 2003-08-18 | |
DKPA200301180 | 2003-08-18 | ||
DKPA200301305 | 2003-09-11 | ||
US52024603P | 2003-11-14 | 2003-11-14 | |
PCT/DK2004/000545 WO2005016900A1 (en) | 2003-08-18 | 2004-08-18 | Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
IS8265A IS8265A (is) | 2006-01-26 |
IS2848B true IS2848B (is) | 2013-09-15 |
Family
ID=34199055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS8265A IS2848B (is) | 2003-08-18 | 2006-01-26 | Súksínat- og malónatsalt af trans-4-(1R,3S)-6-klór-3-fenýlindan-1-ýl)-1,2,2-trímetýlpíperasíni og notkun sem lyf |
Country Status (15)
Country | Link |
---|---|
US (4) | US7767683B2 (is) |
EP (2) | EP1658276B1 (is) |
JP (3) | JP5043429B2 (is) |
AU (3) | AU2004265022A1 (is) |
BR (2) | BRPI0413595B8 (is) |
CA (2) | CA2536144C (is) |
CY (1) | CY1113039T1 (is) |
HR (2) | HRP20120389T1 (is) |
IL (2) | IL173589A0 (is) |
IS (1) | IS2848B (is) |
MX (2) | MXPA06001838A (is) |
NO (2) | NO20061153L (is) |
NZ (2) | NZ575575A (is) |
PL (1) | PL1658277T3 (is) |
WO (2) | WO2005016900A1 (is) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1628685T3 (da) | 2003-04-25 | 2011-03-21 | Gilead Sciences Inc | Antivirale phosphonatanaloge |
BRPI0413595B8 (pt) | 2003-08-18 | 2021-05-25 | H Lundbeck As | sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto |
US7871991B2 (en) | 2004-07-27 | 2011-01-18 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
WO2006086985A1 (en) * | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
TWI376373B (en) * | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) * | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
JP5544165B2 (ja) * | 2006-05-16 | 2014-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | 血液悪性疾患の処置のための方法および組成物 |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
KR20090076958A (ko) * | 2006-10-06 | 2009-07-13 | 얀센 파마슈티카 엔.브이. | 신규 (s)-(+)-2-(2-클로로페닐)-2-하이드록시-에틸 카바메이트 결정 |
PL2125786T3 (pl) * | 2006-12-21 | 2011-07-29 | Pfizer Prod Inc | Bursztynian 2-((4-(1-metylo-4-(pirydyn-4-ylo)-1h-pirazol-3-ilo)fenoksy)metylo)chinoliny |
CN102065861B (zh) * | 2008-05-07 | 2013-10-16 | H.隆德贝克有限公司 | 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪用于改善认知的用途 |
MX2011000306A (es) * | 2008-07-08 | 2011-03-15 | Gilead Sciences Inc | Sales de compuestos inhibidores de hiv. |
EP2344163A1 (en) * | 2008-10-03 | 2011-07-20 | H. Lundbeck A/S | Oral formulation |
TW201102370A (en) * | 2009-07-07 | 2011-01-16 | Lundbeck & Co As H | Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine |
EP2399904A1 (en) * | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
JP5941410B2 (ja) * | 2010-11-09 | 2016-06-29 | 株式会社カネカ | ハロゲン化インデノン類及びそれを用いた光学活性インダノン類又は光学活性インダノール類の製造方法 |
EP2661427A1 (en) * | 2011-01-07 | 2013-11-13 | H. Lundbeck A/S | Method for resolution of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1r,3s)-6-chloro-3-phenyl-indan, 1-yl)-3,3-dimethyl-piperazine |
TWI552751B (zh) | 2011-06-20 | 2016-10-11 | H 朗德貝克公司 | 投予4-((1r,3s)-6-氯-3-苯基-二氫茚-1-基)-1,2,2-三甲基-哌及其鹽用於治療精神分裂症的方法 |
PL2720989T3 (pl) | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii |
IN2015MN00002A (is) | 2012-07-09 | 2015-10-16 | Lupin Ltd | |
CN104736565B (zh) | 2012-08-21 | 2019-03-12 | 詹森药业有限公司 | 利培酮半抗原的抗体及其用途 |
EP3933406A3 (en) | 2012-08-21 | 2022-04-20 | Janssen Pharmaceutica NV | Antibodies to risperidone and use thereof |
CN104822660A (zh) | 2012-08-21 | 2015-08-05 | 詹森药业有限公司 | 阿立哌唑半抗原及其在免疫测定中的应用 |
TR201910347T4 (tr) | 2012-08-21 | 2019-07-22 | Janssen Pharmaceutica Nv | Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı. |
JP6450314B2 (ja) | 2012-08-21 | 2019-01-09 | ヤンセン ファーマシューティカ エヌ.ベー. | クエチアピンハプテンに対する抗体及びその使用 |
AU2013305907B2 (en) | 2012-08-21 | 2018-01-18 | Saladax Biomedical Inc. | Antibodies to quetiapine and use thereof |
CN110054694B (zh) * | 2012-08-21 | 2024-02-20 | 詹森药业有限公司 | 阿立哌唑半抗原的抗体及其用途 |
EP3663316A1 (en) | 2012-08-21 | 2020-06-10 | Janssen Pharmaceutica NV | Antibodies to aripiprazole and use thereof |
PT2888590T (pt) | 2012-08-21 | 2020-09-11 | Janssen Pharmaceutica Nv | Anticorpos para olanzapina e utilização destes |
CA2882490A1 (en) | 2012-08-21 | 2014-02-27 | Ortho-Clinical Diagnostics, Inc. | Antibodies to paliperidone and use thereof |
AU2013305938B2 (en) | 2012-08-21 | 2017-08-17 | Saladax Biomedical Inc. | Antibodies to paliperidone haptens and use thereof |
AR094054A1 (es) | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
US10435478B2 (en) | 2015-12-17 | 2019-10-08 | Janssen Pharmaceutica Nv | Antibodies to quetiapine and use thereof |
US10444250B2 (en) | 2015-12-17 | 2019-10-15 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
EP3960740B1 (en) | 2017-08-01 | 2023-11-15 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections |
JP2021520382A (ja) | 2018-04-06 | 2021-08-19 | ハー・ルンドベック・アクチエゼルスカベット | 2,2−ジメチルピペラジンの調製方法 |
EP3873885A1 (en) | 2018-10-29 | 2021-09-08 | H. Lundbeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
JP2022509965A (ja) | 2018-12-03 | 2022-01-25 | ハー・ルンドベック・アクチエゼルスカベット | 4-((1R,3S)-6-クロロ-3-フェニル-2,3-ジヒドロ-1H-インデン-1-イル)-1,2,2-トリメチルピペラジン及び4-((1R,3S)-6-クロロ-3-(フェニル-d5)-2,3-ジヒドロ-1H-インデン-1-イル)-2,2-ジメチル-1-(メチル-d3)ピペラジンのプロドラッグ |
US11358934B2 (en) * | 2020-03-23 | 2022-06-14 | Caamtech, Inc. | Crystalline forms of psilacetin |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4031216A (en) * | 1974-08-12 | 1977-06-21 | Knoll A.G. Chemische Fabriken | 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines |
IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
DE3139970A1 (de) * | 1981-10-08 | 1983-04-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
US5026853A (en) * | 1987-04-01 | 1991-06-25 | Janssen Pharmaceutica N.V. | 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide |
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
DE3837710A1 (de) * | 1988-11-07 | 1990-05-10 | Statomat Globe Maschf | Verfahren und vorrichtung zum ausrichten der abgemantelten enden von rundkabeln |
JP2667294B2 (ja) | 1991-11-05 | 1997-10-27 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗剤 |
CA2091204C (en) * | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
JPH06184132A (ja) * | 1992-12-22 | 1994-07-05 | Kotobuki Seiyaku Kk | ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤 |
ATE159706T1 (de) | 1993-11-30 | 1997-11-15 | Pfizer | Verfahren zur herstellung von chiralen tetralonen |
CA2132411A1 (en) * | 1994-09-19 | 1996-03-20 | Michael Trani | Enzymatic esterification of long-chain racemic acids and alcohols |
US6455736B1 (en) | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
US6410794B1 (en) | 1994-12-16 | 2002-06-25 | Uop Llc | Process for preparation of pharmaceutically desired chiral tetralone from tetralones |
US5807897A (en) * | 1996-03-01 | 1998-09-15 | Zeneca Limited | Aminotetralin derivative and compositions and method of use thereof |
US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
ES2211080T3 (es) | 1998-05-01 | 2004-07-01 | Pfizer Products Inc. | Procedimiento para la produccion de sertralina tetralona enantiomericamente pura u opticamente enriquecida usando cromatografia continua. |
EP1080078B1 (en) | 1998-05-22 | 2006-02-01 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
DE19824470A1 (de) * | 1998-05-30 | 1999-12-02 | Boehringer Ingelheim Pharma | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
FR2786769B1 (fr) * | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
EP1059302A1 (en) | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
JP2000351773A (ja) * | 1999-06-08 | 2000-12-19 | Yamanouchi Pharmaceut Co Ltd | フラン誘導体からなる医薬 |
AR031520A1 (es) | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
US6369226B1 (en) * | 1999-06-21 | 2002-04-09 | Agouron Pharmaceuticals, Inc. | Substituted benzamide inhibitors of rhinovirus 3C protease |
IN187170B (is) | 2000-01-04 | 2002-02-23 | Sun Pharmaceutical Ind Ltd | |
BRPI0413595B8 (pt) * | 2003-08-18 | 2021-05-25 | H Lundbeck As | sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto |
WO2006086985A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
-
2004
- 2004-08-18 BR BRPI0413595A patent/BRPI0413595B8/pt not_active IP Right Cessation
- 2004-08-18 AU AU2004265022A patent/AU2004265022A1/en not_active Abandoned
- 2004-08-18 EP EP04739041A patent/EP1658276B1/en active Active
- 2004-08-18 CA CA2536144A patent/CA2536144C/en not_active Expired - Fee Related
- 2004-08-18 PL PL04762772T patent/PL1658277T3/pl unknown
- 2004-08-18 MX MXPA06001838A patent/MXPA06001838A/es active IP Right Grant
- 2004-08-18 EP EP04762772A patent/EP1658277B1/en active Active
- 2004-08-18 JP JP2006523528A patent/JP5043429B2/ja not_active Expired - Fee Related
- 2004-08-18 WO PCT/DK2004/000545 patent/WO2005016900A1/en active Application Filing
- 2004-08-18 MX MXPA06001938A patent/MXPA06001938A/es not_active Application Discontinuation
- 2004-08-18 CA CA002536073A patent/CA2536073A1/en not_active Abandoned
- 2004-08-18 US US10/568,572 patent/US7767683B2/en active Active
- 2004-08-18 WO PCT/DK2004/000546 patent/WO2005016901A1/en active Application Filing
- 2004-08-18 NZ NZ575575A patent/NZ575575A/en not_active IP Right Cessation
- 2004-08-18 NZ NZ544715A patent/NZ544715A/en not_active IP Right Cessation
- 2004-08-18 AU AU2004265021A patent/AU2004265021B2/en not_active Ceased
- 2004-08-18 BR BRPI0413555-5A patent/BRPI0413555A/pt not_active IP Right Cessation
- 2004-08-18 US US10/568,292 patent/US7772240B2/en not_active Expired - Fee Related
- 2004-08-18 JP JP2006523529A patent/JP5144930B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-26 IS IS8265A patent/IS2848B/is unknown
- 2006-02-07 IL IL173589A patent/IL173589A0/en unknown
- 2006-02-16 IL IL173788A patent/IL173788A/en unknown
- 2006-03-10 NO NO20061153A patent/NO20061153L/no unknown
- 2006-03-10 NO NO20061151A patent/NO332048B1/no not_active IP Right Cessation
-
2010
- 2010-06-22 US US12/820,392 patent/US8227607B2/en active Active
- 2010-07-30 AU AU2010206058A patent/AU2010206058C1/en not_active Ceased
- 2010-11-04 US US12/939,904 patent/US8076342B2/en not_active Expired - Fee Related
-
2011
- 2011-07-13 JP JP2011154382A patent/JP5553802B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-09 HR HRP20120389TT patent/HRP20120389T1/hr unknown
- 2012-05-24 CY CY20121100469T patent/CY1113039T1/el unknown
- 2012-12-10 HR HRP20121010TT patent/HRP20121010T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS2848B (is) | Súksínat- og malónatsalt af trans-4-(1R,3S)-6-klór-3-fenýlindan-1-ýl)-1,2,2-trímetýlpíperasíni og notkun sem lyf | |
NO2017051I1 (no) | Kariprazin, eventuelt i form av et salt, inkludert kariprazin hydroklorid | |
IS7946A (is) | Lyf | |
CY2013029I1 (el) | Νεα παραγωγα ινσουλινης | |
AU2003241327A1 (en) | Amidinylphenyl compounds and their use as fungicides | |
IS2761B (is) | Ný amínóbensófenónefnasambönd | |
DE602004020680D1 (de) | Die aktivität von gamma-secretase blockierende malonamidderivate | |
IL172733A0 (en) | Diphenylpyridine derivatives, preparation and therapeutic application thereof | |
NO20044322L (no) | Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament | |
NO20080412L (no) | Ny fysiologisk forbindelse Nesfatin, forbindelse relevant dertil og anvendelse av forbindelsene | |
PL1651604T3 (pl) | Związki N-´2-(2-pirydynylo)etylobenzamidy i ich zastosowanie jako środki grzybobójcze | |
HK1096960A1 (en) | Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h- chromium-6-yl-derivatives and drugs containing said compounds | |
IS8491A (is) | Nýtt efnasamband, samsvarandi blöndur, framleiðslu- og/eða meðhöndlunaraðferðir | |
DE602004030605D1 (de) | Herstellung von titanoxid | |
DE60326053D1 (de) | Superfeine salmeterol zubereitung | |
AU2003274202A8 (en) | Novel difluorinated gem compounds, preparation methods thereof and applications of same | |
DK1658277T3 (da) | Succinat- og malonatsalt af trans-4-(1r,3s)-6-chlor-3-phenylindan-1-yl)-1,2,2-trimethylpiperazin og anvendelse som medikament | |
AU2003294952A1 (en) | 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same | |
AU2003206975A1 (en) | Self-destructing syringe | |
AU2003295057A1 (en) | Novel lipophilic compounds and uses thereof | |
AU2003294574A8 (en) | Catheter loop manager | |
DE602004005966D1 (de) | Kombination von arzneimitteln gegen diabetes | |
FI20021817A0 (fi) | Kanyyli | |
SE0202516D0 (sv) | Novel compounds, their use, and preparation | |
IL152397A0 (en) | Development of novel anti-hyperglycemic drugs |